2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory Committee
2022
Hospitalizations of Children Aged 5–11 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022
Shi D, Whitaker M, Marks K, Anglin O, Milucky J, Patel K, Pham H, Chai S, Kawasaki B, Meek J, Anderson E, Weigel A, Henderson J, Lynfield R, Ropp S, Muse A, Bushey S, Billing L, Sutton M, Talbot H, Price A, Taylor C, Havers F, Team C. Hospitalizations of Children Aged 5–11 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022. MMWR Morbidity And Mortality Weekly Report 2022, 71: 574-581. PMID: 35446827, PMCID: PMC9042359, DOI: 10.15585/mmwr.mm7116e1.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationCOVID-19-Associated Hospitalization Surveillance NetworkIntensive care unitAge groupsUnvaccinated childrenPfizer-BioNTech COVID-19 vaccineCumulative hospitalization rateNon-Hispanic black childrenSevere COVID-19Immunization Practices recommendationsUnderlying medical conditionsCDC's Advisory CommitteeImportance of vaccinationEmergency use authorizationUnderlying health conditionsCOVID-19 vaccineCOVID-19SARS-CoV-2Advisory CommitteeCare unitHospitalization ratesVaccination coverageSevere outcomesChildren Aged 5Medical conditions